Amoéba has received a 120-day emergency market authorisation from the French Ministry of Agriculture for its biocontrol product Axpera to combat downy mildew on grapevines in France. This approval allows large-scale field trials from mid-April to mid-August 2025, covering up to 250 hectares, supported by the French Wine and Vine Institute. The milestone represents another validation of Amoéba's innovative biocontrol application, and while significant sales are not yet expected in 2025, the early...
We initiate coverage on Amoéba, an industrial biotechnology company based in Chassieu, France, that focuses on innovative uses of the amoeba Willaertia magna C2c Maky. The company aims to become a major player in the global biocontrol market for plant protection as well as the cosmetics market. Based on a DCF/SOTP analysis, we issue a € 1.7 TP and Buy rating.
Edison Investment Research Limited Edison issues report on Amoéba (ALMIB) 21-Jun-2024 / 12:36 GMT/BST The issuer is solely responsible for the content of this announcement. London, UK, 21 Juni 2024 Edison issues report on Amoéba (ALMIB) to view the full report. All reports published by Edison are available to download free of charge from its website Edison is authorised and regulated by the . Edison is not an adviser or broker-dealer and does not provide investment advice. Edison’s reports are not solicitations to buy or sell any securities. For more information, p...
Amoéba has achieved promising results for the use of its amoeba-based active ingredient in skincare cosmetics in a series of lab and human volunteer trials. In addition, the company secured regulatory approval in the United States and a recommendation for approval in the European Union in 2022 for the active ingredient used in its innovative biological fungicides. Since then, it has tested this active ingredient in standalone and blended use and hopes to achieve product approvals by H125. Amoéba...
Thus far, FY23 has marked a year of successful advancement for Amoéba: (1) the development of its biocontrol plant is ongoing, poised to achieve production of 40 tonnes per annum of W. magna lysate; (2) a third scientific article has been published, which highlights the efficacy of its biocontrol product; and (3) the company has announced a potential further application for W. magna lysate in cosmetic skincare. The new application will not hinder advancement of the biological fungicide product. ...
LA VALEUR DU JOUR : ACTIA GROUP : Feedback Conférence Portzamparc – Conserver (3), obj. 4.70€ Cours: 4.67€ au 21/06/23 AFYREN : Feedback Conférence Portzamparc – Acheter (1), obj. 9.40€ Cours: 5.70€ au 21/06/23 AMOEBA : Feedback Conférence Portzamparc – Acheter (1), obj. 0.72€ Cours: 0.58€ au 21/06/23 BENETEAU : Feedback Conférence Portzamparc – Acheter (1), obj. 23.0€ Cours: 15.3€ au 21/06/23 EXAIL TECHNOLOGIES : Feedback Conférence Portzamparc – Acheter (1), obj. 26.5€ Cours: 20.2€ au 21/...
Following on from the press release in March that provided preliminary data on the FY22 results, Amoéba has published its FY22 universal registration document, which contains detailed financial information for the year. We leave our FY23 estimates unchanged.
Amoéba is a cleantech company committed to the ecological transition through two main applications, the objective of which is to reduce the use of chemical products that are devastating for the environment and health. Amoéba's technology is based on the amoeba Willaertia magna, a type of micro-organism that is still little exploited, unlike bacteria, which are essential for wastewater treatment, or yeast. We initiate coverage of Amoéba with a Strong Buy (1) recommendation and a target price of €...
Amoéba est une cleantech engagée dans la transition écologique à travers deux applications principales, dont l’objectif est de réduire l’usage de produits chimiques dévastateurs pour l’environnement et la santé. La technologie d'Amoéba repose sur l’amibe Willaertia magna, un type de micro-organisme encore peu exploité, contrairement aux bactéries, indispensables au traitement des eaux usées ou encore aux levures. Nous initions la couverture d'Amoéba avec une recommandation Acheter (1) et un obje...
LA VALEUR DU JOUR : ABIVAX : Le cash burn croît en lien avec le lancement d’ABTECT – Acheter (1), obj. 15.5€ Cours: 13.2€ au 19/04/23 AMOEBA : L’amibe au service de l’environnement – Initiation de couverture – Acheter (1) , obj. 0.72€ Cours: 0.63€ au 19/04/23 CERINNOV : REX au RDV, désendettement en prime / Contact – Acheter (1), obj. 3.20€ Cours: 2.22€ au 19/04/23 DBV TECHNOLOGIES : Les 1-3 ans sur le chemin réglementaire de l’AMM aux US – Acheter (1), obj. 7.50€ Cours: 2.99€ au 19/04...
FY22 was an exceptional year for Amoéba in which it secured regulatory approval in the United States and a recommendation for approval in the European Union for the active substance used in its innovative biological fungicides. Now that these essential regulatory hurdles have been cleared, the company intends to construct a production plant capable initially of manufacturing sufficient active substance annually to treat 100,000 hectares of crops, 200,000 hectares when extended. Management plans ...
During 2022 Amoéba secured regulatory approval in the United States and a recommendation for approval in the European Union for the active substance used in its innovative biological fungicides. It is now looking to raise €45m to fund operations and site expansion over the next three years. €23m of the financing will be for capital expenditure, primarily on a production plant capable initially of manufacturing sufficient active substance annually to treat 100,000 hectares of crops, 200,000 hecta...
Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
Le principal objet de la présente assemblée est l'autorisation d'émettre 300 Obligations Convertibles en Actions de 20 000 € de nominal (soit au totale une émission de 6 M€ en nominal) au bénéfice d'une société de droit suisse, Nice & Green.La société indique que cette opération s'inscrit dans s stratégie de renforcement des fonds propres. Si l’on comprend les raisons évoquées par la société, elle n’explique cependant pas pourquoi elle a choisi de faire une émission sans DPS au lieu d’une émissi...
Amoéba: (CORPORATE, Fair Value EUR13 (+192%)) H1 2018 bottom line impacted by restructuring expenses - all eyes on potential US approval Amoeba unveiled its H1 2018 results on Friday evening with revenue at EUR62k vs. EUR75k last year. H1 2018 net income was down yoy mainly due to the impact from restructuring expenses as announced by the company earlier this year. The group's cash position stood at EUR6.3m at end-June vs. EUR7.38m at end-April. The current cash position should enable the compa...
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.